A Phase 2 interventional study of Prolastin-C, 60 mg/kg and Prolastin-C, 120 mg/kg in Emphysema and Alpha 1-antitrypsin Deficiency (AATD), sponsored by Grifols Therapeutics LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-05-20.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 11th largest by enrollment, is one of 4 that started in 2010, is one of 6 in phase 2, and was the 8th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2010.
This study's enrollment of 30 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
12 studies in alpha 1-Antitrypsin Deficiency by Grifols: 2 open now, 2 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 2, and was the 4th registered.
Grifols’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Grifols’s 12 in alpha 1-Antitrypsin Deficiency:
This tab as a report to print or save as PDF → With an account.
This is a study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg of Prolastin-C (alpha1-proteinase inhibitor [alpha1-PI] [Human]), compared to weekly infusions of 60 mg/kg of Prolastin-C in patients with alpha 1-antitrypsin deficiency (AATD).
The question of whether higher doses of alpha1-PI (>60 mg/kg) are able to provide better protection to patients with alpha 1-antitrypsin deficiency is currently unknown. As a first step to address this question, the present study has been undertaken. This is a multi-center, randomized, double-blind, crossover study to assess the safety and pharmacokinetics of weekly infusions of 120 mg/kg of Prolastin-C, compared to weekly infusions of 60 mg/kg of Prolastin-C in patients with alpha 1-antitrypsin deficiency. This study is a crossover design with 2 treatment sequences:
Treatment Sequence 1: 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg weekly infusion of Prolastin-C for 8 weeks (starting at Week 1) (total of 16 treatment weeks)
Treatment Sequence 2: 120 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (starting at Week 11) (total of 16 treatment weeks)
Approximately 15 subjects are planned to be entered into each treatment sequence.
At Weeks 8 to 11 and Weeks 18 to 21, a total of 15 serial blood samples for each subject will be drawn for pharmacokinetic analysis. The expected duration of the study subject's participation will be approximately 25 weeks (which includes a 3-Week Screening Phase, 2-Week Washout Period [between different alpha-1 PI treatment doses], and a 4-Week Follow-up Period). The following safety parameters will be assessed: adverse events, pulmonary exacerbations, vital signs, pulmonary function tests, and clinical laboratory tests.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
This study's enrollment of 30 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Browse alpha 1-Antitrypsin Deficiency studies →Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
First submitted before Grifols Therapeutics LLC became part of Grifols.
Compared within alpha 1-Antitrypsin Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Emphysema. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
Biological: Prolastin-C, 60 mg/kg
120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
Biological: Prolastin-C, 120 mg/kg
Drug page: Alpha 1-Antitrypsin
60 mg/kg weekly infusion of Prolastin-C for 8 weeks
Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), Modified Process, Alpha-1 MP
Drug page: Alpha 1-Antitrypsin
120 mg/kg weekly infusion of Prolastin-C for 8 weeks
Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), Modified Process, Alpha-1 MP
Subjects With Treatment-Emergent Adverse Events (TEAEs)
Number of subjects experiencing at least one TEAE. TEAEs were defined as any adverse event (AE) during the study that began on or after the date of first dose of investigational product (i.e., Prolastin-C).
Time frame: 22 weeks
Subjects With Drug-Related TEAE(s)
Number of subjects with at least one TEAE that was determined by the Investigator to be either "possibly related" or "related" to the investigational product (i.e., Prolastin-C).
Time frame: 22 weeks
Subjects With Treatment-Emergent Serious Adverse Events (SAEs)
Number of subjects who experienced at least one treatment-emergent SAE.
Time frame: 22 weeks
Subjects Withdrawn Due to an AE(s)
Number of subjects who were withdrawn from the study due to at least one AE.
Time frame: 22 weeks
Subjects With Treatment-Emergent Pulmonary Exacerbation(s)
Number of subjects with at least one treatment-emergent pulmonary exacerbation
Time frame: 22 weeks
Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s)
Number of subjects who experienced at least one severe TEAE or pulmonary exacerbation.
Time frame: 22 weeks
Number of TEAEs
Total number of TEAEs reported.
Time frame: 22 Weeks
Number of Drug-related TEAEs
Total number of drug-related TEAEs reported
Time frame: 22 Weeks
Number of Treatment-Emergent Pulmonary Exacerbations
Total number of treatment-emergent pulmonary exacerbations.
Time frame: 22 Weeks
AUC0-7days
Area Under the Alpha-1 PI Concentration-Time Curve from Day 0 to Day 7
Time frame: Week 8 and Week 18 at the following timepoints: 0 (pre-infusion), completion of first infusion bag, completion of 2nd infusion bag, and 15 min, 30 min, and 1, 2, 4, 8, 24, 48, 120, and 168 hours post-dose
Mean Trough
The average trough concentration at steady-state, calculated as the mean value using the four Trough measurements obtained at Weeks 6, 7, 8 and at 7 days (168 hours) post infusion at Week 8 for the first treatment period or prior to the start of the infusions at Weeks 16, 17, 18, and at 7 days (168 hours) post infusion at Week 18 for the second treatment period.
Time frame: Single measurment immediately prior to infusion at Weeks 6, 7, 8, 9 and Weeks 16, 17, 18, 19
| Milestone | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
| Milestone | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
| Milestone | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
| Milestone | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
Number of subjects experiencing at least one TEAE. TEAEs were defined as any adverse event (AE) during the study that began on or after the date of first dose of investigational product (i.e., Prolastin-C).
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects With Treatment-Emergent Adverse Events (TEAEs) | 23 | 18 |
Area Under the Alpha-1 PI Concentration-Time Curve from Day 0 to Day 7
| h*mg/mL | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| AUC0-7days | 203.6 ± 20.48 | 344.8 ± 46.53 |
Number of subjects with at least one TEAE that was determined by the Investigator to be either "possibly related" or "related" to the investigational product (i.e., Prolastin-C).
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects With Drug-Related TEAE(s) | 3 | 1 |
Number of subjects who experienced at least one treatment-emergent SAE.
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects With Treatment-Emergent Serious Adverse Events (SAEs) | 0 | 0 |
Number of subjects who were withdrawn from the study due to at least one AE.
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects Withdrawn Due to an AE(s) | 0 | 0 |
Number of subjects with at least one treatment-emergent pulmonary exacerbation
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects With Treatment-Emergent Pulmonary Exacerbation(s) | 7 | 5 |
Number of subjects who experienced at least one severe TEAE or pulmonary exacerbation.
| participants | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s) | 0 | 0 |
The average trough concentration at steady-state, calculated as the mean value using the four Trough measurements obtained at Weeks 6, 7, 8 and at 7 days (168 hours) post infusion at Week 8 for the first treatment period or prior to the start of the infusions at Weeks 16, 17, 18, and at 7 days (168 hours) post infusion at Week 18 for the second treatment period.
| μM | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Mean Trough | 17.3 ± 2.36 | 27.7 ± 3.75 |
Total number of TEAEs reported.
| Events | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Number of TEAEs | 69 | 43 |
Total number of drug-related TEAEs reported
| Events | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Number of Drug-related TEAEs | 5 | 1 |
Total number of treatment-emergent pulmonary exacerbations.
| Events | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| Number of Treatment-Emergent Pulmonary Exacerbations | 9 | 6 |
Collected over Adverse events were assessed from the time of informed consent through the end of study visit; thus, AEs were assessed for up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 60 mg/kg Prolastin-C | — | 0/30 (0%) | 15/30 (50%) |
| 120 mg/kg Prolastin-C | — | 0/30 (0%) | 10/30 (33.3%) |
| Event | 60 mg/kg Prolastin-C | 120 mg/kg Prolastin-C |
|---|---|---|
| COPD ExacerbationRespiratory, thoracic and mediastinal disorders | 7/30 | 5/30 |
| Urinary Tract InfectionInfections and infestations | 3/30 | 0/30 |
| ContusionInjury, poisoning and procedural complications | 1/30 | 2/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/30 | 0/30 |
| ProteinuriaRenal and urinary disorders | 2/30 | 1/30 |
| Blood Creatinine IncreasedInvestigations | 0/30 | 2/30 |
| Blood Glucose IncreasedInvestigations | 0/30 | 2/30 |
Demographic and other baseline characteristics were analyzed on the intent-to-treat population, which included all subjects who were randomized.
| Age Continuous(years) | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence | Total |
|---|---|---|---|
| Mean | 59.7 ± 6.89 | 57.4 ± 6.34 | 58.6 ± 6.62 |
| Sex: Female, Male(Participants) | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 7 | 7 | 14 |
| Race (NIH/OMB)(Participants) | 60 mg/kg - 120 mg/kg Prolastin-C Treatment Sequence | 120 mg/kg - 60 mg/kg Prolastin-C Treatment Sequence | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 15 | 15 | 30 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Nov 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →